CS
AVIR icon

Candriam SCA’s Atea Pharmaceuticals AVIR Stock Holding History

Candriam SCA’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-135,316
Closed -$417K – 732
2023
Q1 		$417K Sell
135,316
-58,640
-30% -$238K ﹤0.01% 813
2022
Q4 		$933K Buy
193,956
+64,627
+50% +$327K 0.01% 710
2022
Q3 		$736K Buy
+129,329
New +$990K 0.01% 772

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's AVIR Position: Q2 2023 in Review

Candriam SCA sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 135,316 shares — an estimated $417K sold.

Candriam SCA first reported a position in AVIR in Q3 2022 and held it in 3 quarters. The position peaked at $933K in Q4 2022. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Candriam SCA reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 135,316 Atea Pharmaceuticals shares in Q2 2023, an estimated $417K.
  • Candriam SCA first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Candriam SCA's Atea Pharmaceuticals position peaked at $933K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.